David J Llewellyn
Overview
Explore the profile of David J Llewellyn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
4047
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Underwood B, Lourida I, Gong J, Tamburin S, Tang E, Sidhom E, et al.
Alzheimers Dement (N Y)
. 2025 Jan;
11(1):e70037.
PMID: 39839078
Abstract: Recent clinical trials on slowing dementia progression have led to renewed focus on finding safer, more effective treatments. One approach to identify plausible candidates is to assess whether existing...
2.
Ward D, Flint J, Littlejohns T, Foote I, Canevelli M, Wallace L, et al.
JAMA Neurol
. 2024 Nov;
82(1):61-71.
PMID: 39527039
Importance: An accessible marker of both biological age and dementia risk is crucial to advancing dementia prevention and treatment strategies. Although frailty is a candidate for that role, the nature...
3.
Aizawa K, Jordan A, Gooding K, Llewellyn D, Mawson D, Casanova F, et al.
J Hypertens
. 2024 Sep;
42(12):2139-2147.
PMID: 39248140
Objective: Hypertension is a recognized risk factor for the development of cognitive impairment and dementia in older adults. Aortic stiffness and altered haemodynamics could promote the transmission of detrimental high...
4.
Pain O, Jones A, Al Khleifat A, Agarwal D, Hramyka D, Karoui H, et al.
Heliyon
. 2024 Aug;
10(15):e35342.
PMID: 39170265
Introduction: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. This study integrates common genetic association results from the latest ALS genome-wide association study (GWAS) summary statistics with functional genomic...
5.
Hendriks S, Ranson J, Peetoom K, Lourida I, Tai X, de Vugt M, et al.
JAMA Neurol
. 2023 Dec;
81(2):134-142.
PMID: 38147328
Importance: There is limited information on modifiable risk factors for young-onset dementia (YOD). Objective: To examine factors that are associated with the incidence of YOD. Design, Setting, And Participants: This...
6.
Newby D, Orgeta V, Marshall C, Lourida I, Albertyn C, Tamburin S, et al.
Alzheimers Dement
. 2023 Oct;
19(12):5952-5969.
PMID: 37837420
Introduction: A wide range of modifiable risk factors for dementia have been identified. Considerable debate remains about these risk factors, possible interactions between them or with genetic risk, and causality,...
7.
Marzi S, Schilder B, Nott A, Sala Frigerio C, Willaime-Morawek S, Bucholc M, et al.
Alzheimers Dement
. 2023 Sep;
19(12):5970-5987.
PMID: 37768001
Introduction: Experimental models are essential tools in neurodegenerative disease research. However, the translation of insights and drugs discovered in model systems has proven immensely challenging, marred by high failure rates...
8.
Winchester L, Harshfield E, Shi L, Badhwar A, Al Khleifat A, Clarke N, et al.
Alzheimers Dement
. 2023 Sep;
19(12):5860-5871.
PMID: 37654029
With the increase in large multimodal cohorts and high-throughput technologies, the potential for discovering novel biomarkers is no longer limited by data set size. Artificial intelligence (AI) and machine learning...
9.
Bucholc M, James C, Al Khleifat A, Badhwar A, Clarke N, Dehsarvi A, et al.
Alzheimers Dement
. 2023 Aug;
19(12):5934-5951.
PMID: 37639369
Artificial intelligence (AI) and machine learning (ML) approaches are increasingly being used in dementia research. However, several methodological challenges exist that may limit the insights we can obtain from high-dimensional...
10.
Bettencourt C, Skene N, Bandres-Ciga S, Anderson E, Winchester L, Foote I, et al.
Alzheimers Dement
. 2023 Aug;
19(12):5905-5921.
PMID: 37606627
Genetics and omics studies of Alzheimer's disease and other dementia subtypes enhance our understanding of underlying mechanisms and pathways that can be targeted. We identified key remaining challenges: First, can...